5-isobutylisoxazol-3-ol | 10004-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-isobutylisoxazol-3-ol
• 英文别名: 5-isobutyl-isoxazol-3-one；5-(2-Methylpropyl)-1,2-oxazol-3-one
• CAS: 10004-49-6
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: GKRIFEXGXVBLEA-UHFFFAOYSA-N

物化性质

• 沸点：
  128-133 °C(Press: 3 Torr)
• 密度：
  1.049±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-isobutylisoxazol-3-ol 在 氢溴酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 18.0h， 生成 4-(Bromomethyl)-2-(methoxymethyl)-5-(2-methylpropyl)-1,2-oxazol-3-one
  参考文献：
  名称：

  Excitatory amino-acid receptor agonists. Synthesis and pharmacology of analogues of 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid

  摘要：

  We have previously proposed the existence of a lipophilic cavity of the 2-amino-3-(3-hydroxy-5-methylisoxazol4-yl)propionic acid (AMPA) receptor recognition site capable of accommodating alkyl substituents of limited size in the 5-position of the isoxazole ring. In order to indirectly elucidate the approximate extent of this proposed cavity we have synthesized and pharmacologically characterized a number of AMPA analogues. For most of these AMPA analogues, a positive correlation between AMPA receptor affinity and agonist effect was observed. The only exception was demethyl-AMPA (8a), which showed relatively high AMPA receptor affinity (IC50 = 0.27 mu M) but remarkably weak agonist potency (EC50 = 900 mu M). Whereas the ethyl analogue of AMPA (Et-AMPA) (IC50 = 0.030 mu M; EC50 = 2.3 mu M) has previously been shown to be slightly more potent than AMPA (IC50 = 0.040 mu M; EC50 = 3.5 mu M), substitutions of a propyl or a butyl group for the methyl group of AMPA to give 8b (IC50 = 0.090 mu M; EC50 = 5.0 mu M) or 8f (IC50 = 1.0 mu M; EC50 = 32 mu M), respectively, result in progressive loss of the AMPA agonist effect. Analogues containing larger groups, such as isopentyl (8e), 1-propylbutyl (8g), 2,2-dimethylpropyl (8h), or benzyl (14) groups, were very weak or totally inactive as AMPA receptor ligands.

  DOI：

  10.1016/s0223-5234(97)89085-x
• 作为产物：
  描述：

  tert-butyl tert-butoxycarbonyloxy(5-methyl-3-oxohexanoyl)carbamate 在 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.5h， 以66%的产率得到5-isobutylisoxazol-3-ol
  参考文献：
  名称：

  3-Oxoisoxazole-2(3H)-carboxamides and isoxazol-3-yl carbamates: Resistance-breaking acetylcholinesterase inhibitors targeting the malaria mosquito, Anopheles gambiae

  摘要：

  To identify potential selective and resistance-breaking mosquitocides against the African malaria vector Anopheles gambiae, we investigated the acetylcholinesterase (AChE) inhibitory and mosquitocidal properties of isoxazol-3-yl dimethylcarbamates (15), and the corresponding 3-oxoisoxazole-2(3H)-dimethylcarboxamide isomers (14). In both series, compounds were found with excellent contact toxicity to wild-type susceptible (G3) strain and multiply resistant (Akron) strain mosquitoes that carry the G119S resistance mutation of AChE. Compounds possessing good to excellent toxicity to Akron strain mosquitoes inhibit the G119S mutant of An. gambiae AChE (AgAChE) with k(i) values at least 10-to 600-fold higher than that of propoxur, a compound that does not kill Akron mosquitoes at the highest concentration tested. On average, inactivation of WT AgAChE by dimethylcarboxamides 14 was 10-20 fold faster than that of the corresponding isoxazol-3-yl dimethylcarbamates 15. X-ray crystallography of dimethylcarboxamide 14d provided insight into that reactivity, a finding that may explain the inhibitory power of structurally-related inhibitors of hormone-sensitive lipase. Finally, human/An. gambiae AChE inhibition selectivities of these compounds were low, suggesting the need for additional structural modification. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.01.026

文献信息

• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• INDAZOLE DERIVATIVES
  申请人：Buchler Ingrid Price

  公开号：US20110028447A1

  公开（公告）日：2011-02-03

  This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) wherein R 1 , R 2 and R 3 are as defined in this specification.

  这项发明涉及化合物、药物组合物和治疗由CB1受体活性介导的哺乳动物主体（包括人类）疾病的方法，包括向需要这种治疗的哺乳动物中施用化合物的治疗有效剂量，其化合物的结构式为（I），其中R1、R2和R3如本说明书中所定义。
• Cyclic boronic acid ester derivatives and methods of making the same
  申请人：Rempex Pharmaceuticals, Inc.

  公开号：US10004758B2

  公开（公告）日：2018-06-26

  Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

  本文公开了抗菌化合物组合物、药物组合物及其用途和制备方法。 某些实施方案涉及环硼酸酯衍生物及其作为治疗剂的用途。
• Albicidin derivatives, their use and synthesis
  申请人：TECHNISCHE UNIVERSITAET BERLIN

  公开号：US10308595B2

  公开（公告）日：2019-06-04

  Antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which include carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections are also disclosed.

  抗生素活性化合物，其特征为通式(I)，其中X1、BB、BC、BD、BE和X2为结构单元，D1、D2、D3、D4或D5为连接体，包括碳原子、硫原子、氮原子、磷原子和/或氧原子，并分别以共价方式连接摩尔体BA和BB、BB和BC、BC和BD、BD和BE以及BE和BF，其中特别是结构单元BC包括氨基酸衍生物。还公开了用于疾病治疗方法，特别是用于细菌感染治疗方法的化合物。
• BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3122750B1

  公开（公告）日：2019-09-04